| Solution Information | help | |
| Enzyme: | Mu-type opioid receptor | |
| inhibitor: | BDBM114631 | |
| substrate: | n/a | |
| Solution Type: | Aqueous | |
| pH at Preparation: | n/a | |
| Temp. Prep.: | n/a | |
| Comments: | Assay Overview: The purpose of this assay is to determine whether powder samples of compounds identified as HTR2A activator probe candidates are nonselective activators of beta-arrestin signaling or activate the mu (OPRM1) opioid receptor. This assay determines dose response curves. The assay monitors GPCR-beta-arrestin proximity using low affinity fragment complementation of beta-galactosidase (beta-gal). This assay employs U2OS cells which express OPRM1 fused to a beta-gal peptide fragment (enzyme donor), and beta-arrestin fused to the complementary beta-gal fragment (enzyme acceptor). Cells are incubated with test compound, followed by measurement of well luminescence. As designed, compounds that activate OPRM1 will cause beta-arrestin recruitment, resulting in reconstitution of the beta-gal holoenzyme. The reconstituted holoenzyme can then catalyze the hydrolysis of a substrate (GalactonStarSubstrateTM) which yields a chemiluminescent signal, resulting in increased well luminesc | |
| If you find an error in this entry please send us an E-mail | ||